Champions Oncology Earnings Estimate

CSBR Stock  USD 4.55  0.28  6.56%   
By analyzing Champions Oncology's earnings estimates, investors can diagnose different trends across Champions Oncology's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Champions Oncology is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Champions Oncology is projected to generate 0.01 in earnings per share on the 31st of October 2024. Champions Oncology earnings estimates module stress-tests analyst consensus about projected Champions Oncology EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Champions Oncology, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Champions Oncology Revenue Breakdown by Earning Segment

By analyzing Champions Oncology's earnings estimates, investors can diagnose different trends across Champions Oncology's analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Champions Oncology's Gross Profit is relatively stable compared to the past year. As of 11/22/2024, Gross Profit Margin is likely to grow to 0.53, while Pretax Profit Margin is likely to drop (0.15).
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Champions Oncology Earnings per Share Projection vs Actual

About Champions Oncology Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Champions Oncology earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Champions Oncology estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Champions Oncology fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-84.6 M-80.4 M
Retained Earnings Total Equity-69.6 M-73.1 M
Earnings Yield(0.11)(0.12)
Price Earnings Ratio(9.03)(8.58)
Price Earnings To Growth Ratio(0.23)(0.22)

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

  0.4KTTAW Pasithea TherapeuticsPairCorr
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.